Bibliometric and visual analysis of global research on snake venom disintegrins (2009–2023)

doi:10.5246/jcps.2024.11.073

Abstract

Abstract:

Snake venom disintegrins, through their inhibition of integrin-related binding, effectively impede both cell-cell and cell-matrix interactions as well as signal transduction pathways, rendering them promising candidates for lead therapeutics across a spectrum of diseases. This study aimed to conduct a comprehensive bibliometric analysis, elucidating recent trends in disintegrin research. Using relevant keywords, we meticulously explored the Web of Science Core Collection (WOSCC) database. Employing CiteSpace and VOSviewer, we conducted an exhaustive analysis, encompassing 142 documents published between 2009 and 2023. These publications, dispersed across 74 journals, involved 670 authors representing 207 institutes spanning 42 countries. Notably, the United States contributed the highest number of records, with Texas A&M University emerging as the most prolific institution. Within this landscape, Elda E. Sanchez emerged as the foremost author, and Toxicon emerged as the predominant journal. Keyword analysis underscored prevailing research foci, with an emphasis on expression, in vitro experimentation, and ASP-containing peptides. This study presented a comprehensive overview of disintegrin research globally, spanning the period from 2009 to 2023, and held potential utility in guiding future research endeavors. By identifying current research hotspots, our findings offered invaluable insights to shape forthcoming investigations in this dynamic field.

Key words: Snake venom disintegrins, Biblimetric analysis, CiteSpace, VOSviewer, Research trends

Supporting:

Yinxiang Lan, Xiuliang Qiu, Dandan Huang. Bibliometric and visual analysis of global research on snake venom disintegrins (2009–2023)[J]. Journal of Chinese Pharmaceutical Sciences, 2024, 33(11): 1012-1024.

Figures/Tables 18

Table 1. The top nine most productive countries.

Table 2. The top 10 productive organizations.

Table 3. The top five authors by number of publications.

Table 4. The top five citation journals.

Table 5. The top five co-citation journals.

Table 6. The top five co-cited articles on disintegrin-related research.

Table 7. The top 20 keyword co-occurrence.

References 31

[1]	Lazarovici, P.; Marcinkiewicz, C.; Lelkes, P.I. From snake venom’s disintegrins and C-type lectins to anti-platelet drugs. Toxins. 2019, 11, 303.
[2]	Vasconcelos, A.A.; Estrada, J.C.; Caruso, I.P.; Kurtenbach, E.; Zingali, R.B.; Almeida, F.C.L. Toward the mechanism of jarastatin (rJast) inhibition of the integrin αVβ3. Int. J. Biol. Macromol. 2024, 255, 128078.
[3]	Lucena, S.E.; Romo, K.; Suntravat, M.; Sánchez, E.E. Anti-angiogenic activities of two recombinant disintegrins derived from the Mohave and Prairie rattlesnakes. Toxicon. 2014, 78, 10–17.
[4]	Kuo, Y.J.; Chung, C.H.; Huang, T.F. From discovery of snake venom disintegrins to A safer therapeutic antithrombotic agent. Toxins. 2019, 11, 372.
[5]	Liu, S.C.; Sun, Y.; Zhang, T.; Cao, L.T.; Zhong, Z.W.; Cheng, H.X.; Wang, Q.Q.; Qiu, Z.; Zhou, W.M.; Wang, X.L. Upconversion nanoparticles regulated drug & gas dual-effective nanoplatform for the targeting cooperated therapy of thrombus and anticoagulation. Bioact. Mater. 2022, 18, 91–103.
[6]	Sanchez, E.F.; Flores-Ortiz, R.J.; Alvarenga, V.G.; Eble, J.A. Direct fibrinolytic snake venom metalloproteinases affecting hemostasis: structural, biochemical features and therapeutic potential. Toxins. 2017, 9, 392.
[7]	Arruda Macêdo, J.K.; Fox, J.W.; de Souza Castro, M. Disintegrins from snake venoms and their applications in cancer research and therapy. Curr. Protein Pept. Sci. 2015, 16, 532–548.
[8]	Lucena, S.; Rodríguez-Acosta, A.; Grilli, E.; Alfonso, A.; Goins, A.; Ogbata, I.; Walls, R.; Suntravat, M.; Uzcátegui, N.L.; Guerrero, B.; Sánchez, E.E. The characterization of trans-Pecos copperhead (Agkistrodon contortrix pictigaster) venom and isolation of two new dimeric disintegrins. Biologicals. 2016, 44, 191–197.
[9]	Vasconcelos, A.A.; Estrada, J.C.; David, V.; Wermelinger, L.S.; Almeida, F.C.L.; Zingali, R.B. Structure-function relationship of the disintegrin family: sequence signature and integrin interaction. Front. Mol. Biosci. 2021, 8, 783301.
[10]	Cesar, P.H.S.; Braga, M.A.; Trento, M.V.C.; Menaldo, D.L.; Marcussi, S. Snake venom disintegrins: an overview of their interaction with integrins. Curr. Drug Targets. 2019, 20, 465–477.
[11]	Zhang, Y.; Lu, L.; Zheng, R. Emerging trends and focus on immune checkpoint inhibitors for non-small cell lung cancer treatment: visualization and bibliometric analysis. Frontiers in pharmacology. 2023, 14, 1140771.
[12]	Zhang, M.; Kou, L.; Qin, Y.Y.; Chen, J.W.; Bai, D.Z.; Zhao, L.; Lin, H.Y.; Jiang, G.H. A bibliometric analysis of the recent advances in diazepam from 2012 to 2021. Front. Pharmacol. 2022, 13, 1042594.
[13]	Guo, J.S.; Wang, H.; Li, Y.; Zhu, S.; Hu, H.X.; Gu, Z.J. Nanotechnology in coronary heart disease. Acta Biomater. 2023, 171, 37–67.
[14]	Wang, Q.; Yang, K.L.; Zhang, Z.; Wang, Z.; Li, C.; Li, L.; Tian, J.H.; Ye, Y.J.; Wang, S.; Jiang, K.W. Characterization of global research trends and prospects on single-cell sequencing technology: bibliometric analysis. J. Med. Internet Res. 2021, 23, e25789.
[15]	Wang, Y.; Rao, Y.F.; Lin, Z.J.; Sa, R.N.; Yin, Y.L.; Zhang, X.M.; Zhang, B. Current status and trends of research on anthracycline-induced cardiotoxicity from 2002 to 2021: a twenty-year bibliometric and visualization analysis. Oxid. Med. Cell Longev. 2022, 2022, 6260243.
[16]	Sabe, M.; Chen, C.M.; Perez, N.; Solmi, M.; Mucci, A.; Galderisi, S.; Strauss, G.P.; Kaiser, S. Thirty years of research on negative symptoms of schizophrenia: a scientometric analysis of hotspots, bursts, and research trends. Neurosci. Biobehav. Rev. 2023, 144, 104979.
[17]	Ling, L.X.; Ouyang, Y.B.; Hu, Y. Research trends on nanomaterials in gastric cancer: a bibliometric analysis from 2004 to 2023. J. Nanobiotechnol. 2023, 21, 248.
[18]	Zhao, J.; Liao, B.; Gong, L.; Yang, H.Y.; Li, S.; Li, Y.S. Knowledge mapping of therapeutic cancer vaccine from 2013 to 2022: a bibliometric and visual analysis. Hum. Vaccin. Immunother. 2023, 19, 2254262.
[19]	Yu, Z.Y.; Xie, L.; Zhang, J.; Lin, H.; Niu, T. The evolution of minimal residual disease: key insights based on a bibliometric visualization analysis from 2002 to 2022. Front. Oncol. 2023, 13, 1186198.
[20]	Guo, Y.; Zhang, H.Q.; Yu, X.Q. A bibliometric analysis of complement in IgA nephropathy from 1991 to 2022. Front. Pharmacol. 2023, 14, 1200193.
[21]	Zhang, Y.; Liu, X.Y.; Qiao, X.F.; Fan, Y.B. Characteristics and emerging trends in research on rehabilitation robots from 2001 to 2020: bibliometric study. J. Med. Internet Res. 2023, 25, e42901.
[22]	Yang, X.L.; Yin, H.; Zhang, D.Y.; Peng, L.S.; Li, K.L.; Cui, F.; Xia, C.C.; Li, Z.S.; Huang, H.J. Bibliometric analysis of cathepsin B research from 2011 to 2021. Frontiers in medicine, 2022, 9, 898455.
[23]	Li, F.C.; Zhang, D.; Li, Z.; Hou, Z.M.; Chen, W.; Chen, J.; Hu, Y.Q. Exploring the landscape of stem cell research for Alzheimer’s disease: a bibliometric analysis spanning 2002–2021. J. Chin. Pharm. Sci. 2023, 32, 813.
[24]	Sofyantoro, F.; Yudha, D.S.; Lischer, K.; Nuringtyas, T.R.; Putri, W.A.; Kusuma, W.A.; Purwestri, Y.A.; Swasono, R.T. Bibliometric analysis of literature in snake venom-related research worldwide (1933-2022). Anim. Basel. 2022, 12, 2058.
[25]	Succar, B.B.; Saldanha-Gama, R.F.G.; Valle, A.S.; Wermelinger, L.S.; Barja-Fidalgo, C.; Kurtenbach, E.; Zingali, R.B. The recombinant disintegrin, jarastatin, inhibits platelet adhesion and endothelial cell migration. Toxicon. 2022, 217, 87–95.
[26]	Seo, M.J. ;Choi, H.J.;Chung, K.H.Pyun, Y.R. Production of a platelet aggregation inhibitor, salmosin, by high cell density fermentation of recombinant escherichia coli. J. Microbiol. Biotechnol. 2011, 21, 1053–1056.
[27]	Danilucci, T.M.; Santos, P.K.; Pachane, B.C.; Pisani, G.F.D.; Lino, R.L.B.; Casali, B.C.; Altei, W.F.; Selistre-de-Araujo, H.S. Recombinant RGD-disintegrin DisBa-01 blocks integrin αvβ3 and impairs VEGF signaling in endothelial cells. Cell Commun. Signal. 2019, 17, 27.
[28]	Higuchi, D.A.; Almeida, M.C.; Barros, C.C.; Sanchez, E.F.; Pesquero, P.R.; Lang, E.A.S.; Samaan, M.; Araujo, R.C.; Pesquero, J.B.; Pesquero, J.L. Leucurogin, a new recombinant disintegrin cloned from Bothrops leucurus (white-tailed-jararaca) with potent activity upon platelet aggregation and tumor growth. Toxicon. 2011, 58, 123–129.
[29]	David, V.; Succar, B.B.; de Moraes, J.A.; Saldanha-Gama, R.F.G.; Barja-Fidalgo, C.; Zingali, R.B. Recombinant and chimeric disintegrins in preclinical research. Toxins. 2018, 10, 321.
[30]	Kolvekar, N.; Bhattacharya, N.; Sarkar, A.; Chakrabarty, D. How snake venom disintegrins affect platelet aggregation and cancer proliferation. Toxicon. 2023, 221, 106982.
[31]	Akhtar, B.; Muhammad, F.; Sharif, A.; Anwar, M.I. Mechanistic insights of snake venom disintegrins in cancer treatment. Eur. J. Pharmacol. 2021, 899, 174022.